Shimura Tatsuo, Kofunato Yasuhide, Okada Ryo, Yashima Rei, Koyama Yoshihisa, Araki Kenichiro, Kuwano Hiroyuki, Takenoshita Seiichi
Department of Organ Regulatory Surgery, Fukushima Medical University, Fukushima 960-1295, Japan.
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
Oncol Lett. 2017 Jul;14(1):819-829. doi: 10.3892/ol.2017.6252. Epub 2017 May 25.
Galectin-3 has been reported to be associated with the prognosis of patients with various malignancies; however, it has not yet been investigated in patients with extrahepatic cholangiocarcinoma (EHCC). Expression of galectin-3 was retrospectively examined in 58 patients with EHCC: 21 with perihilar cholangiocarcinoma and 37 with distal cholangiocarcinoma (DCC). The Cox proportional hazard model was used to identify independent prognostic factors. Intranuclear accumulation of galectin-3 (gal-3-INA) was associated with poorer overall survival (OS) in all patients (P=0.003), as well as in patients with DCC (P=0.004). Patients with gal-3-INA also exhibited a poorer disease-free survival (DFS) than those without gal-3-INA in all patients with EHCC (P<0.001), and in patients with DCC (P<0.001). Gal-3-INA was an independent prognostic factor of OS and DFS in all patients [OS: Hazard ratio (HR), 4.470; 95% confidence interval (CI), 1.759-11.357; P=0.002; and DFS: HR, 5.116; 95% CI, 2.025-12.925; P=0.001]. Gal-3-INA was also an independent prognostic factor in patients with DCC (OS: HR, 2.979; 95% CI, 1.035-8.570; P=0.043; and DFS: HR, 6.773; 95% CI, 1.558-29.439; P=0.011). In the analysis of patients with DCC, the number of patients with high galectin-3 expression (P=0.038), recurrence (P<0.001), distant metastases (P<0.001), R0 status (P=0.029) or microscopic vascular invasion (P=0.019) was significantly higher in the gal-3-INA-positive group than in the gal-3-INA-negative group. In conclusion, gal-3-INA was identified as a strong prognostic factor for OS and DFS in patients with DCC.
据报道，半乳糖凝集素-3与多种恶性肿瘤患者的预后相关；然而，其在肝外胆管癌（EHCC）患者中的情况尚未得到研究。对58例EHCC患者进行回顾性研究，其中21例为肝门部胆管癌，37例为远端胆管癌（DCC），检测半乳糖凝集素-3的表达情况。采用Cox比例风险模型确定独立预后因素。在所有患者（P=0.003）以及DCC患者（P=0.004）中，半乳糖凝集素-3核内积聚（gal-3-INA）与较差的总生存期（OS）相关。在所有EHCC患者（P<0.001）以及DCC患者（P<0.001）中，有gal-3-INA的患者无病生存期（DFS）也比无gal-3-INA的患者差。Gal-3-INA是所有患者OS和DFS的独立预后因素[OS：风险比（HR），4.470；95%置信区间（CI），1.759 - 11.357；P=0.002；DFS：HR，5.116；95%CI，2.025 - 12.925；P=0.001]。Gal-3-INA也是DCC患者的独立预后因素（OS：HR，2.979；95%CI，1.035 - 8.570；P=0.043；DFS：HR，6.773；95%CI，1.558 - 29.439；P=0.011）。在DCC患者分析中，gal-3-INA阳性组中半乳糖凝集素-3高表达（P=0.038）、复发（P<0.001）、远处转移（P<0.001）、R0状态（P=0.029）或微血管侵犯（P=0.019）的患者数量显著高于gal-3-INA阴性组。总之，gal-3-INA被确定为DCC患者OS和DFS的强预后因素。
